Oct 19, 2026 07:16AM
Oct 19, 2026 07:15AM
Oct 19, 2026 07:00AM
Oct 19, 2026 07:00AM
Sep 16, 2026 07:00AM
Aug 18, 2026 08:11AM
Aug 18, 2026 02:52AM RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform
Aug 17, 2026 12:07PM
Aug 17, 2026 07:01AM
Aug 17, 2026 07:00AM
Aug 14, 2026 04:32PM
Aug 5, 2026 07:00AM
Jul 30, 2026 07:01AM
Jul 30, 2026 07:00AM EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Jul 16, 2026 07:00AM
Jul 13, 2026 07:00AM
Jun 16, 2026 07:00AM
May 19, 2026 07:00AM
May 18, 2026 07:00AM
May 14, 2026 07:01AM
May 14, 2026 07:00AM EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
May 6, 2026 07:00AM
Apr 29, 2026 07:00AM
Apr 16, 2026 04:01PM
Mar 16, 2026 07:00AM
Mar 4, 2026 07:00AM
Mar 2, 2026 07:00AM
Mar 2, 2026 07:00AM EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
Feb 25, 2026 07:00AM
Feb 24, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 17, 2026 07:00AM
Feb 5, 2026 07:00AM
Jan 16, 2026 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 7, 2026 09:02AM
Jan 7, 2026 07:03AM
Jan 7, 2026 07:00AM
Dec 21, 2025 08:00PM
Dec 17, 2025 07:00AM
Dec 16, 2025 07:00AM
Dec 9, 2025 10:49AM Mizuho on EyePoint Inc. (EYPT): 'Competitor Makes a Move for the Pole Position; Reiterate OP, as We're Not Concerned'
Nov 19, 2025 07:00AM
Nov 19, 2025 07:00AM
Nov 17, 2025 07:00AM
Nov 5, 2025 07:00AM
Nov 3, 2025 07:00AM
Oct 29, 2025 07:00AM
Oct 16, 2025 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 14, 2025 10:43PM

335,202 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All